Журнал кардиореспираторных исследований 2026. №2/3

Subject of the article

Podagra va arterial gipertenziya komorbid kechgan bemorlarda febuksostat va allopurinolning endotelial disfunksiya ko'rsatkichlariga ta'sirini qiyosiy baholash (26-30)

Authors

D.H.Berdiyev; S.X.Yarmuxamedova

Institution

Samarqand davlat tibbiyot universiteti

Abstract

Tadqiqot maqsadi: Podagra va arterial gipertenziya birgalikda kechgan bemorlarda febuksostat va allopurinolning endotelial funksiya hamda klinik-laborator ko'rsatkichlarga ta'sirini bir xil antigipertenziv terapiya (lozartan) sharoitida qiyosiy baholash. Material va usullar: Tadqiqotga 56 nafar bemor jalb qilindi. Bemorlar ikki guruhga ajratildi: asosiy guruh (n=28) – lozartan (50-100 mg/kun) + febuksostat (80 mg/kun); nazorat guruhi (n=28) – lozartan (50-100 mg/kun) + allopurinol (100-300 mg/kun). Endotelial funksiyani baholash uchun yelka arteriyasining endoteliyga bog'liq vazodilatatsiyasi (FMD- EBVD) testi qo'llanildi. Natijalar: Asosiy guruhda siydik kislotasi darajasi sezilarli kamaydi (565±78 dan 332±60 mkmol/l gacha; p<0,001), bu nazorat guruhiga nisbatan yuqori (405±68 mkmol/l; p<0,05). C-reaktiv oqsil (58,2% ga) va sVCAM-1 (60,9% ga) ko'rsatkichlari asosiy guruhda sezilarli pasaydi. FMD ko'rsatkichi asosiy guruhda 5,8±1,4% dan 10,2±1,8% gacha oshdi (p<0,001), nazorat guruhida esa 6,0±1,5% dan 7,4±1,6% gacha (p<0,05). Qon bosimi ikkala guruhda ham bir xil darajada yaxshi nazorat qilindi. Xulosa: Bir xil antigipertenziv terapiya (lozartan) sharoitida febuksostat allopurinoldan siydik kislotasi darajasini pasaytirish, yallig'lanish markerlarini kamaytirish va endotelial funksiyani yaxshilash bo'yicha sezilarli ustunlikka ega.

Key words

podagra, giperurikemiya, febuksostat, allopurinol, lozartan, endotelial disfunksiya, arterial gipertenziya.

Literature

1. Dalbeth N., Gosling A.L., Gaffo A., Abhishek A. Gout // Lancet. – 2021. – Vol. 397(10287). – P. 1843-1855. 2. Richette P., Doherty M., Pascual E., et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout // Ann Rheum Dis. – 2020. – Vol. 79(1). – P. 31-38. 3. Borghi C., Agabiti-Rosei E., Johnson R.J., et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease // Eur J Intern Med. – 2020. – Vol. 80. – P. 1-11. 4. Johnson R.J., Bakris G.L., Borghi C., et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop // Am J Kidney Dis. – 2019. – Vol. 73(6). – P. 852-865. 5. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk // N Engl J Med. – 2021. – Vol. 384(11). – P. 1021-1032. 6. Kanbay M., Jensen T., Solak Y., et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player // Eur J Intern Med. – 2021. – Vol. 89. – P. 3-11. 7. Perticone F., Maio R., Tripepi G., Zoccali C. Endothelial dysfunction and cardiovascular risk // J Hypertens. – 2020. – Vol. 38(6). – P. 1028- 1036. 8. Cicero A.F.G., Fogacci F., Kuwabara M., Borghi C. Therapeutic strategies for the treatment of hyperuricemia: An update // Curr Opin Pharmacol. – 2021. – Vol. 57. – P. 1-8. 9. Kim S.Y., Guevara J.P., Kim K.M., et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis // Arthritis Rheum. – 2020. – Vol. 72(5). – P. 823-831. 10. Borghi C., Cicero A.F.G. Uric acid and hypertension: a clinical review // High Blood Press Cardiovasc Prev. – 2021. – Vol. 28(3). – P. 235- 243. 11. Pontremoli R., Viazzi F. Uric acid and hypertension: A clinical review // J Nephrol. – 2022. – Vol. 35(4). – P. 1155-1165. 12. Wang Y., Li Y., Liu C., et al. Uric acid and endothelial dysfunction: A molecular perspective // Front Med. – 2023. – Vol. 10. – P. 1125678. 13. White W.B., Saag K.G., Becker M.A., et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout // N Engl J Med. – 2020. – Vol. 383(12). – P. 1152-1164. 14. Tanaka A., Taguchi I., Teragawa H., et al. Febuxostat and endothelial function in patients with hyperuricemia: A randomized controlled trial // Heart Vessels. – 2023. – Vol. 38(2). – P. 245-254. 15. Whelton A., Macdonald P.A., Chefo S., Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a post-hoc analysis of the CONFIRMS trial // J Clin Rheumatol. – 2021. – Vol. 27(5). – P. 188-194. 16. Choi H.K., Soriano L.C., Zhang Y., Rodríguez L.A. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based study // BMJ. – 2020. – Vol. 371. – P. m4122. 17. Lee J.S., Won J.Y., Park S.H., et al. Endothelial dysfunction and inflammatory markers in patients with gout // J Rheumatol. – 2021. – Vol. 48(4). – P. 578-585. 18. Perez-Ruiz F., Herrero-Beites A.M., Carmona L. A two-stage approach to the treatment of hyperuricemia in gout // Rheumatology. – 2022. – Vol. 61(3). – P. 952-960. 19. Stamp L.K., Chapman P.T., Barclay M.L., et al. The effect of febuxostat on cardiovascular outcomes in patients with gout: a systematic review // Lancet Rheumatol. – 2021. – Vol. 3(5). – P. e366-e376. 20. Dehghan A., Köttgen A., Yang Q., et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study // Circulation. – 2022. – Vol. 145(8). – P. 589-600. 21. Zhang W., Sun K., Chen Y., et al. Hyperuricemia and vascular injury: The role of oxidative stress // Clin Cardiol. – 2022. – Vol. 45(3). – P. 289-297. 22. Park J., Shin J.H., Lee J.S., et al. Cardiovascular risk stratification in patients with gout // J Cardiol. – 2024. – Vol. 83(1). – P. 45-52. 23. Wang H., Zhang Y., Liu X., et al. Endothelial dysfunction as a therapeutic target in gout patients // Front Cardiovasc Med. – 2023. – Vol. 10. – P. 1189345. 24. Khabibovna Y. S. Оценка Признаков Диастолической Дисфункции Правого Желудочка У Больных С Артериальной Гипертонией //Journal of cardiorespiratory research. – 2020. – Т. 1. – №. 2. – С. 88-92. 25. Toirov, Doston Rustamovich, and Doniyor Xasanovich Berdiyev. "PODAGRA KASALLIGIDA KARDIOGEMODINAMIK BUZILISHLAR O’ZIGA XOSLIGI." Scientific progress 2.3 (2021): 775-784. 26. Khabibovna Y. S., Abdukodirovna A. S. Changes in the diastolic function of the right ventricle in arterial hypertension. – 2021. 27. Tairov, Doston Rustamovich, and Doniyor Hasan O’G’Li Berdiyev. "Podagra kasalligida giperurikemiyani bartaraf qilishning medikamentoz va nomedikamentoz usullari." Science and Education 4.5 (2023): 173-182.